Evidence map›Paper›PMID 35761110›Full record

ArticleArchives of osteoporosis2022

Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece.

Maria P Yavropoulou, Polyzois Makras, Kostas Athanasakis, Vasiliki-Kalliopi Bournia, Konstantinos Mathioudakis, Anastasios Tsolakidis, Eva Kassi, Gregory Kaltsas, Panagiota Mitrou, Petros P Sfikakis

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of osteoporosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Association of hyponatremia with bone mineral density and fractures: a narrative review.Therapeutic advances in endocrinology and metabolism · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Maria P YavropoulouΕndocrinology Unit, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens Medical School, Athens, 11527, Greece. myavropoulou@med.uoa.gr.
Polyzois MakrasDepartment of Endocrinology and Diabetes, Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, Athens, 11525, Greece.
Kostas AthanasakisLaboratory for Health Technology Assessment (LabHTA), Department of Public Health Policy, School of Public Health, University of West Attica, Athens, 11521, Greece.
Vasiliki-Kalliopi BourniaFirst Department of Propaedeutic and Internal Medicine and Joint Academic Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, 11527, Greece.
Konstantinos MathioudakisIDIKA SA - E-Government Center for Social Security Services, Athens, Greece.
Anastasios TsolakidisIDIKA SA - E-Government Center for Social Security Services, Athens, Greece.
Eva KassiΕndocrinology Unit, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens Medical School, Athens, 11527, Greece.
Gregory KaltsasΕndocrinology Unit, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens Medical School, Athens, 11527, Greece.
Panagiota MitrouIndependent Department of Therapeutic Protocols and Patient Registries, Hellenic Republic Ministry of Health, Athens, Greece.
Petros P SfikakisFirst Department of Propaedeutic and Internal Medicine and Joint Academic Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, 11527, Greece.
National and Kapodistrian University of Athens · GRCenter for Security Studies · GRHellenic Air Force · GRMinistry of Health · GRUniversity of West Attica · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We used the Greek nationwide database to capture individuals on anti-osteoporotic treatment during 2019. From the estimated number of 683,679 osteoporotic individuals, only 42% were receiving treatment, with the total annual cost being almost one-tenth of the total cost of fractures. The treatment gap was significantly higher in males than in females.

introductionBased on the 2019 European scorecard (SCOPE), osteoporosis is diagnosed in an estimated 683,679 individuals in Greece, with the direct cost of incident fractures being €694.7 million, although further relevant real-world data are scarce.

methodsThe e-Government Center for Social Security Services prescription database, which covers almost 100% of the Greek population, was used to capture all individuals on anti-osteoporotic treatment during 2019.

resultsA total of 288,983 among 8,641,341 people, corresponding to 3.3% of the total adult Greek population, had filled at least one anti-osteoporotic prescription (6.0% and 0.36% for females and males, respectively). Prevalence of anti-osteoporotic treatment increased with age, from 0.15% in those younger than 50 to 8.6% in those older than 70 years. Oral bisphosphonates were more frequently prescribed (58.8%), followed by denosumab (39.4%). Alendronate was more frequently prescribed in males and in people younger than 60 years. Denosumab was more frequently prescribed in females and in people older than 60 years. Selective estrogen-receptor modulators, teriparatide, and parenteral bisphosphonates accounted for 1.1%, 1.0%, and 0.02% of all prescriptions, respectively. Orthopedic surgeons (39.6%), endocrinologists (19.6%), general practitioners (19%), and rheumatologists (9.3%) prescribed the vast majority of anti-osteoporotic regimens, with significant differences in prescription patterns. The annual cost of treatment per patient increased significantly with age, being on average €323.33.

conclusionsLess than half of the estimated number of individuals with osteoporosis in 2019 in Greece received treatment, with the total annual cost being far less than the estimated cost of incident-fragility fractures. The impact of this undertreatment on related health care costs merits further investigation.

Indexed as

Bone Density Conservation AgentsFractures, BoneOsteoporosisOsteoporotic FracturesAgedDenosumabDiphosphonatesFemaleGreeceHumansMalePrevalenceBone Density Conservation AgentsDenosumabDiphosphonatesBisphosphonates, GreeceDenosumabOsteoporosisReal-world dataTreatment gap

Identifiers

PMID35761110
OpenAlexW4283693506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.